AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether AZD2171 can effectively improve time to
tumour progression when added to fulvestrant in patients with advanced hormone sensitive
breast cancer who progressed on prior hormonal therapy.